Press Releases
IXICO announces £1.9 million new study award
IXICO plc, the AI data analytics company delivering insights in neuroscience, today announces that it has executed a contract to provide neuroimaging services that will support a phase Ib/II clinical trial for Huntington’s disease.
Read more
IXICO is awarded multiple Alzheimer’s disease contracts
IXICO plc, the data analytics company delivering insights in neuroscience, announces that it has secured new contracts in Alzheimer’s disease (AD) clinical trials.
Read more
IXICO secures additional Huntington’s disease contracts
IXICO plc, the data analytics company delivering insights in neuroscience, announces that it has secured new contracts in Huntington’s disease (HD) clinical trials.
Read more
Trading Update for year ended 30 September 2020
Data analytics service strategy drives growth Remote access, technology-driven, business model demonstrates resilience during COVID-19 Order book growth underpins strong forward revenue visibility IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, announces a trading update for the year ended 30 September 2020.
Read more
IXICO to Present at SCA & ARCA Global Conference
IXICO plc announces that Dr Robin Wolz, Senior Vice President of Science & Innovation at IXICO, will present on the industry panel at the virtual SCA & ARCA Global Conference, taking place on 19-21 October 2020.
Read more
IXICO and NYU Langone Health sign agreement to develop novel imaging markers in multiple system atrophy
IXICO plc announces that it has entered into an agreement with NYU Langone Health to support a trial to determine if the immunosuppressant drug Sirolimus – approved by the FDA to prevent organ transplant rejection and for the treatment of a rare and progressive lung disease called lymphangioleiomiomatosis - is also able to slow the...
Read more
>£2m contract extension win in Huntington's disease
IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, has executed a c. £2m contract to provide additional imaging services that will support a pivotal Huntington's disease (HD) study. This builds on the Company's existing contract to support our 'top-20' pharma client's Phase III study in HD.
Read more
IXICO joins the TRACK-FA Neuroimaging Consortium to develop novel imaging markers in Friedreich's Ataxia
IXICO plc announces that it has entered into a 5 year collaboration with the Friedreich's Ataxia Research Alliance (FARA), a non-profit organization dedicated to the pursuit of scientific research leading to treatments and a cure for Friedreich's Ataxia (FA).
Read more1-8 of 37 results